glycated fibronectin

12/01/2020 - "Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study."
10/01/2023 - "Glycosylated fibronectin improves first-trimester prediction of pre-eclampsia."
10/01/2023 - "Screening for pre-eclampsia by maternal serum glycosylated fibronectin at 11-13 weeks' gestation."
09/19/2023 - "Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation."
02/24/2020 - "Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study."

10/01/2020 - "Glycosylated fibronectin as a first trimester marker for gestational diabetes."
10/12/2016 - "Screening of gestational diabetes mellitus in early pregnancy by oral glucose tolerance test and glycosylated fibronectin: study protocol for an international, prospective, multicentre cohort trial."
09/01/2013 - "Glycosylated fibronectin as a first-trimester biomarker for prediction of gestational diabetes."

08/01/2022 - "Our results demonstrate that in pregnant women with hypertension, glycosylated fibronectin is useful for predicting maternal and fetal morbidity occurring within 10 days of testing. "
08/01/2022 - "To evaluate the usefulness of glycosylated fibronectin (GlyFn) as point-of-care (POC) test for triaging and managing hypertension cases in pregnancy. "
08/01/2022 - "Glycosylated Fibronectin Point-of-care Test for Triage and Surveillance of Hypertension in Pregnancy Cases: A Retrospective Observational Case Control Study."
12/01/2023 - "Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed pre-eclampsia in women with chronic hypertension."
11/01/2023 - "Prediction using serum glycosylated fibronectin of imminent pre-eclampsia in women with new-onset hypertension."

04/01/2016 - "Compared with the control group, the aerobic exercise group showed a significant decrease in cellular fibronectin, glycosylated hemoglobin, insulin resistance, fasting insulin, fasting blood sugar, and lipid profile after 12 weeks of aerobic exercise. "
04/01/2016 - "To examine changes in cellular fibronectin, glycosylated hemoglobin, insulin resistance, fasting insulin, fasting blood sugar, and lipid profile, 5 ml of blood was taken from the brachial vein of patients before and 48 hours after completion of the exercise period and after 12 hours of fasting at rest. "
01/01/2017 - "These include glycemic markers (fasting glucose, post-load glucose, hemoglobin A1C), inflammatory markers (C-reactive protein, tumor necrosis factor-alpha), insulin resistance markers (fasting insulin, sex hormone-binding globulin), adipocyte-derived markers (adiponectin, leptin), placenta-derived markers (follistatin-like-3, placental growth factor, placental exosomes), and others (e.g., glycosylated fibronectin, soluble (pro)renin receptor, alanine aminotransferase, ferritin). "

11/01/1995 - "There is a positive correlation between the myofibroblast phenotype formation, cellular proliferation and the occurrence of ED-A and ED-B containing fibronectin, as well as de novo glycosylated fibronectin in Dupuytren's disease. "
11/01/1995 - "Differential expression of fibronectin splice variants, oncofetal glycosylated fibronectin and laminin isoforms in nodular palmar fibromatosis."
11/01/1995 - "The tissue formation process in nodular palmar fibromatosis (Morbus Dupuytren) was investigated by the demonstration of fibronectin splice variants (ED-A and ED-B fibronectin), de novo glycosylated fibronectin and laminin isoforms (A, M, B1, B2, s chains) in association to the proliferative activity (Ki-67 antigen) and the occurrence of myofibroblast phenotype (alpha-smooth muscle actin, desmin). "
12/01/1995 - "To investigate a possible implication of these growth factors in the tissue formation process of palmar fibromatosis, TGF beta 1/2 and bFGF synthesis, as well as TGF beta 1/3 and bFGF tissue distribution, is demonstrated by RNA in situ hybridization and/or immunohistochemistry in relation to myofibroblast phenotype development (alpha-smooth muscle actin, desmin immunohistochemistry), expression of different fibronectin isoforms (ED-A+, ED-B+ and oncofetal glycosylated fibronectin immunohistochemistry, fibronectin RNA in situ hybridization) and cellular activity (cyclin RNA in situ hybridization, Ki-67 immunolabelling). "